interesting email – then silence
Question:
Thanks for the welcome. No I wouldn’t invest at this point – at least not until the price stabilizes. It has pretty much dropped in half, and the volume has really slowed down the last two days. It could easily drop by another 20-25% unless they announce some verification of their trials in Venezuela. Mark By the way -Off topic – has anyone ever related any concern about antibiotic use and the onset of P? M
Response:
In some languages there are no other words that describe "half a cure". — Regards Gil Teva 20 Mekor Haim street Jerusalem 93465 Israel Tel: +972 2 6724273 Mobile: +972-54-948642
Response:
> > Have you made much $$$ from stockscapes leads? > Oh, an absolute fortune! Not! I subscribe to these things more for their > humour content than for the commercial possibilities. > Graham > Have been lurking for sometime and really enjoy and appreciate how > helpful everyone is here. I do a lot of stock watching and I know a > little bit about this company.
Welcome to the Group Mark. Would you invest based on this info? I haven’t watched the market machinations, in awhile. this sounds like a blue sky situation? Just to protect the hopefoolishly lemmings on board: >What is the difference between a stock that is listed as>NASDAQ
(national) for example <XTON>>NASDAQ has certain requirements that a company must meet in order toget listed ….>and>>a stock that is listed as>NASDAQ (othcbb) for example <BIGG>If a stock does not meet Nasdaq (or NYSE) requirements (or hasn’tapplied for some reason) it’s considered an Over The Counter orBulletin Board stock. These stocks don’t have any requirements as faras reporting, so often you know very little about them. For thisreason, they are inherently much riskier.>>and what exactly does BLUE SKYED mean??Blue Sky laws are the terms for a set of regulations that the SECimposes on any stock that wants to get *covered* by a broker in theU.S. Meaning, among other things, that brokers can formally recommendthe stocks to their clients. Each state typically has different BlueSky laws, however about 35 of them have united under a commonapplication. BIGG just recently was approved for these 35 states.Getting Blue Skyed gives a company some credibility and is also astepping stone to getting the NASDAQ listing.hope this helps. Great questions, by the way. Lastly, many states have established rulesrequiring the approval of a security by a state security administrator forsecurities sold on the NASDAQ Small Cap Market and the OTCBB market. Theserules are referred to as ‘blue sky laws’ and the first modern state bluesky law was adopted in 1911 in Kansas. The term "blue sky" referred tospeculative schemes that, in the words of a judge of the period, had nomore substance than so many feet of "blue sky." The Kansas law served asthe nationwide model for state regulation of securities offerings and thelicensing of broker dealers and their agents. Check withhttp://www.nasaa.org/bluesky/ and call your State security administratorto determine whether a particular security is licensed for sale in yourstate. &&&&&&&&&&&&&&&&&&&&&& I googled astralis ltd and got 4 hits " " Skyepharma and got 43 hits " " Psoraxine with astralis 4 hits. Some of the hits were from our p ng, no less. Yours included. I think a real company like corixa.com that is in some stage ( 1 2 3 etc) that is on the nasdaq is a little less risky then a pink sheet over the counter stock that reversed into some other shell or name from the wild blue yonder. Of course you could flip a coin and trade commodities with a little less risk. You’ll lose it all only 90% of the time in this situation. BTW, i only googled the groups and not the web. As figures there lie a little deeper under the blue sea then up in the blue yonder. randall… having p and getting p fleeced would be p-pitifool. – Hide quoted text — Show quoted text -> The company which you have been talking about is ASTR OTCBB in the US. > Here are a couple of press release tidbits – sorry for the cut and > paste – the news service I subscribe to doesn’t allow links. Also note > that the stock came on the market in November at 3.20 per share and > closed today at 1.92 – it seems to be dropping with the rest of the > biotechs – the Nasdaq biotech index peaked in early Dec at 96 and > closed at just under 75 today - down 5.5 % today. > A couple of notes > Astralis LTD, an emerging biotechnology company based in New Jersey, > focuses on > the research and development of novel treatments for immune system > disorders and > skin diseases. Psoraxine, the company’s first product, is an > innovative drug > under development for psoriasis, and is based on the company’s > discovery of a > new gene sequence of proteins. To date, clinical data suggest > remission of this > skin condition in patient trials in Venezuela. > SkyePharma PLC, an established drug delivery company, based in the UK, > provides > innovative services to major pharmaceutical partners from the point of > drug > discovery through the approval process. Its five technologies, oral, > injectable, > inhalation, topical, and nanoparticulate solubilisation encompass the > vast > majority of delivery systems in use by the pharmaceutical industry. > For more > information, visit SkyePharma’s web site at http://www.skyepharma.com > . > - Skye has a market cap of 330 million pounds. They have some novel > drug delivery methods – and I wonder if they haven’t already tried out > this Psoraxine using their methods – they sure seem to have jumped > into this company. > FLORHAM PARK, N.J., Nov 13, 2001 (BUSINESS WIRE) — Hercules > Development Group > announced today the closing of its definitive merger agreement with > Astralis > LLC. > Simultaneously with the closing, Hercules completed an equity > financing which > raised $3.2 million to assist Astralis in the development, testing and > commercialization of Psoraxine, a drug which has brought about > clinical > remission of Psoriasis during clinical trails conducted in Venezuela. > LONDON, and FLORHAM PARK, N.J., Dec. 12 /PRNewswire — SkyePharma PLC > (Nasdaq: > SKYE; LSE: SKP) and Astralis LTD (OTC Bulletin Board: ASTR) announce > several > agreements concerning the formulation and development of Astralis’ > novel > injectable vaccine therapy, Psoraxine(TM), for the treatment of all > forms of > psoriasis, a chronic skin disorder that affects approximately 3% of > the world > population. > In a separate transaction, SkyePharma will make a total equity > investment in > Astralis of up to US$20 million in convertible preferred shares, on > payment for > which SkyePharma will own 15.3% of Astralis. SkyePharma will make an > initial > investment of US$10 million on signature of the agreement. The > remaining US$10 > million investment will be paid at times and in quantities, amongst > other > conditions, dependent on the date of filing the US IND, up to January > 31, 2003. > Astralis has completed clinical studies in Venezuela using first > generation > Psoraxine to treat 3,000 psoriasis patients, the majority of whom > responded > positively with few side effects. Of the 3,000 treated patients, 638 > achieved > complete remission, whilst nearly half of all patients experienced a > reduction > in disease of between 70% and 90%, as measured by the Psoriasis Area > and > Severity Index (PASI), a validated outcomes measure. Overall, 96% of > the > patients had a positive response to Psoraxine, although these results > have not > yet been independently verified. > Professor James Leyden, a Board member of the American Academy of > Dermatology > and past chairman of the Dermatology Foundation, said, "I have had the > opportunity to review the data generated in Venezuela, and was very > encouraged > by the results. I believe Psoraxine could be an exciting new treatment > alternative for many of the world’s psoriasis sufferers. We look > forward to > becoming an integral part of the ongoing clinical program." > Hope this answers your questions. > Mark
Response:
Maddie, My psychotherapist tells me that there is nothing wrong with a little paranoia. I tend to agree with her. Graham
Response:
> Being paranoid it seems to me that "they" have no interest in curing us > because we are too valuable as consumers of their so called "treatments".
Hi, Graham and Maddie. So, it is obviously to provocative to be real. My best guess is another stock hype to finance some smart operator. Are these smallcaps on the bulletin boards or 100M caps? Or do they even mention pink sheet scam-O-La’s? Have you made much $$$ from stockscapes leads? Maybe these small guys with miracle p help read evetsm’s pubmed in-cite-full syndrome X page and figured it all out. Or, they reversed the chirality of omega 6’s as a result of Mikes1111 and JR’s mysterious borage and primrose cure and have a "miracle" drug that only costs $99.99/week. Of course hope springs eternal. Keep us posted. randall..BTW what is your Hoover index these days G????? – Hide quoted text — Show quoted text -> I subscribe to an investment newsletter called SmallCap from Stockscape. > Last week, the newsletter arrived containing the following article: > a.. Over 180 million people worldwide suffer from Psoriasis > a.. Currently, there is no FDA approved cure for Psoriasis, an often > traumatizing and disabilitating skin disease > a.. At present, Goldman Sachs values the US market for Psoriasis treatment > at over $2 Billion annually > In 24 Hours – A Spectacular New Drug Discovery Gives Hope to Millions > Would you invest in a Company developing a drug that has achieved clinical > remission of a disease affecting over 7 million Americans and an estimated > 180 million people around the world? > Would you be interested to know that this Company has already developed a > strategic relationship with a major London-based pharmaceutical company, > resulting in a recent equity investment of US $20 million? > Keep watching your inbox! At this time tomorrow, SmallCap Central will > send > you a profile on a most compelling investment opportunity. Once this drug > is > developed and deployed, it will belong to a $2 billion dollar US market, > as > reported by Goldman Sachs, and a multi-billion dollar market worldwide! > To learn the name of this Company, and to find out details of this major > medical breakthrough, watch for tomorrow’s email from SmallCap Central. > You can imagine how this caught my interest. Well the promised next days > email never arrived and email to Stockscap have revealed nothing but > silence. Does anyone know about this? > Graham > — > Outgoing mail is certified Virus Free. > Checked by AVG anti-virus system (http://www.grisoft.com).
Response:
Have you made much $$$ from stockscapes leads? Oh, an absolute fortune! Not! I subscribe to these things more for their humour content than for the commercial possibilities. Graham
Response:
> Have you made much $$$ from stockscapes leads? > Oh, an absolute fortune! Not! I subscribe to these things more for their > humour content than for the commercial possibilities. > Graham
Hi, Ok.. i know you like funny ha ha’s. You did give us this. I don’t know if anyone has seen this site, but it provides an insight into the various "personalities" found on most newsgroups. Profoundus Maximus, Netiquette Nazi, Cyber Sisters, Peacemaker etc. Each description in accompanied by an amusing cartoon. http://www.winternet.com/~mikelr/flame1.html And so many found the mirror to be un-beer-able to face the P shone from this reflective site. Did you reek humor or havoc? As the yucks are as hard to come by as the bucks, please keep us appraised of the p possible cure for both applications. randall.. stock scam or more blue sky for wanna be cureds?
Response:
> Have you made much $$$ from stockscapes leads? > Oh, an absolute fortune! Not! I subscribe to these things more for their > humour content than for the commercial possibilities. > Graham
Have been lurking for sometime and really enjoy and appreciate how helpful everyone is here. I do a lot of stock watching and I know a little bit about this company. The company which you have been talking about is ASTR OTCBB in the US. Here are a couple of press release tidbits – sorry for the cut and paste – the news service I subscribe to doesn’t allow links. Also note that the stock came on the market in November at 3.20 per share and closed today at 1.92 – it seems to be dropping with the rest of the biotechs – the Nasdaq biotech index peaked in early Dec at 96 and closed at just under 75 today - down 5.5 % today. A couple of notes Astralis LTD, an emerging biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine, the company’s first product, is an innovative drug under development for psoriasis, and is based on the company’s discovery of a new gene sequence of proteins. To date, clinical data suggest remission of this skin condition in patient trials in Venezuela. SkyePharma PLC, an established drug delivery company, based in the UK, provides innovative services to major pharmaceutical partners from the point of drug discovery through the approval process. Its five technologies, oral, injectable, inhalation, topical, and nanoparticulate solubilisation encompass the vast majority of delivery systems in use by the pharmaceutical industry. For more information, visit SkyePharma’s web site at http://www.skyepharma.com . - Skye has a market cap of 330 million pounds. They have some novel drug delivery methods – and I wonder if they haven’t already tried out this Psoraxine using their methods – they sure seem to have jumped into this company. FLORHAM PARK, N.J., Nov 13, 2001 (BUSINESS WIRE) — Hercules Development Group announced today the closing of its definitive merger agreement with Astralis LLC. Simultaneously with the closing, Hercules completed an equity financing which raised $3.2 million to assist Astralis in the development, testing and commercialization of Psoraxine, a drug which has brought about clinical remission of Psoriasis during clinical trails conducted in Venezuela. LONDON, and FLORHAM PARK, N.J., Dec. 12 /PRNewswire — SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) and Astralis LTD (OTC Bulletin Board: ASTR) announce several agreements concerning the formulation and development of Astralis’ novel injectable vaccine therapy, Psoraxine(TM), for the treatment of all forms of psoriasis, a chronic skin disorder that affects approximately 3% of the world population. In a separate transaction, SkyePharma will make a total equity investment in Astralis of up to US$20 million in convertible preferred shares, on payment for which SkyePharma will own 15.3% of Astralis. SkyePharma will make an initial investment of US$10 million on signature of the agreement. The remaining US$10 million investment will be paid at times and in quantities, amongst other conditions, dependent on the date of filing the US IND, up to January 31, 2003. Astralis has completed clinical studies in Venezuela using first generation Psoraxine to treat 3,000 psoriasis patients, the majority of whom responded positively with few side effects. Of the 3,000 treated patients, 638 achieved complete remission, whilst nearly half of all patients experienced a reduction in disease of between 70% and 90%, as measured by the Psoriasis Area and Severity Index (PASI), a validated outcomes measure. Overall, 96% of the patients had a positive response to Psoraxine, although these results have not yet been independently verified. Professor James Leyden, a Board member of the American Academy of Dermatology and past chairman of the Dermatology Foundation, said, "I have had the opportunity to review the data generated in Venezuela, and was very encouraged by the results. I believe Psoraxine could be an exciting new treatment alternative for many of the world’s psoriasis sufferers. We look forward to becoming an integral part of the ongoing clinical program." Hope this answers your questions. Mark
Response:
I subscribe to an investment newsletter called SmallCap from Stockscape. Last week, the newsletter arrived containing the following article: a.. Over 180 million people worldwide suffer from Psoriasis a.. Currently, there is no FDA approved cure for Psoriasis, an often traumatizing and disabilitating skin disease a.. At present, Goldman Sachs values the US market for Psoriasis treatment at over $2 Billion annually In 24 Hours – A Spectacular New Drug Discovery Gives Hope to Millions Would you invest in a Company developing a drug that has achieved clinical remission of a disease affecting over 7 million Americans and an estimated 180 million people around the world? Would you be interested to know that this Company has already developed a strategic relationship with a major London-based pharmaceutical company, resulting in a recent equity investment of US $20 million? Keep watching your inbox! At this time tomorrow, SmallCap Central will send you a profile on a most compelling investment opportunity. Once this drug is developed and deployed, it will belong to a $2 billion dollar US market, as reported by Goldman Sachs, and a multi-billion dollar market worldwide! To learn the name of this Company, and to find out details of this major medical breakthrough, watch for tomorrow’s email from SmallCap Central. You can imagine how this caught my interest. Well the promised next days email never arrived and email to Stockscap have revealed nothing but silence. Does anyone know about this? Graham
Response:
Being paranoid it seems to me that "they" have no interest in curing us because we are too valuable as consumers of their so called "treatments". – Hide quoted text — Show quoted text -> I subscribe to an investment newsletter called SmallCap from Stockscape. > Last week, the newsletter arrived containing the following article: > a.. Over 180 million people worldwide suffer from Psoriasis > a.. Currently, there is no FDA approved cure for Psoriasis, an often > traumatizing and disabilitating skin disease > a.. At present, Goldman Sachs values the US market for Psoriasis treatment > at over $2 Billion annually > In 24 Hours – A Spectacular New Drug Discovery Gives Hope to Millions > Would you invest in a Company developing a drug that has achieved clinical > remission of a disease affecting over 7 million Americans and an estimated > 180 million people around the world? > Would you be interested to know that this Company has already developed a > strategic relationship with a major London-based pharmaceutical company, > resulting in a recent equity investment of US $20 million? > Keep watching your inbox! At this time tomorrow, SmallCap Central will send > you a profile on a most compelling investment opportunity. Once this drug is > developed and deployed, it will belong to a $2 billion dollar US market, as > reported by Goldman Sachs, and a multi-billion dollar market worldwide! > To learn the name of this Company, and to find out details of this major > medical breakthrough, watch for tomorrow’s email from SmallCap Central. > You can imagine how this caught my interest. Well the promised next days > email never arrived and email to Stockscap have revealed nothing but > silence. Does anyone know about this? > Graham
— Outgoing mail is certified Virus Free. Checked by AVG anti-virus system (http://www.grisoft.com).
Response:
True, I think the word "cure" is incorrectly used in the release (as it generally is). I never expect a "cure", but I would like a tretment that works well. Robb
– Hide quoted text — Show quoted text -> Being paranoid it seems to me that "they" have no interest in curing us > because we are too valuable as consumers of their so called "treatments". > I subscribe to an investment newsletter called SmallCap from Stockscape. > Last week, the newsletter arrived containing the following article: > a.. Over 180 million people worldwide suffer from Psoriasis > a.. Currently, there is no FDA approved cure for Psoriasis, an often > traumatizing and disabilitating skin disease > a.. At present, Goldman Sachs values the US market for Psoriasis treatment > at over $2 Billion annually > In 24 Hours – A Spectacular New Drug Discovery Gives Hope to Millions > Would you invest in a Company developing a drug that has achieved clinical > remission of a disease affecting over 7 million Americans and an estimated > 180 million people around the world? > Would you be interested to know that this Company has already developed a > strategic relationship with a major London-based pharmaceutical company, > resulting in a recent equity investment of US $20 million? > Keep watching your inbox! At this time tomorrow, SmallCap Central will > send > you a profile on a most compelling investment opportunity. Once this drug > is > developed and deployed, it will belong to a $2 billion dollar US market, > as > reported by Goldman Sachs, and a multi-billion dollar market worldwide! > To learn the name of this Company, and to find out details of this major > medical breakthrough, watch for tomorrow’s email from SmallCap Central. > You can imagine how this caught my interest. Well the promised next days > email never arrived and email to Stockscap have revealed nothing but > silence. Does anyone know about this? > Graham > — > Outgoing mail is certified Virus Free. > Checked by AVG anti-virus system (http://www.grisoft.com).
Response:
Related Posts